Alzecure Q2’23: Presented positive phase IIa ACD440 results - Redeye

Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q2 report. We continue to see an interesting neurology platform case with an eventful future ahead and experienced team that manages to produce a lot of research while maintaining cost efficiency.

Länk till analysen i sin helhet: https://www.redeye.se/research/939011/alzecure-q223-presented-positive-phase-iia-acd440-results?utm_source=finwire&utm_medium=RSS